Basilea's antibiotic Zevtera receives Swiss approval
This article was originally published in Scrip
Executive Summary
BasileaPharmaceutica has obtained regulatory approval in Switzerland for Zevtera (ceftobiprole medocaril for injection), a broad-spectrum anti-MRSA cephalosporin antibiotic, for the treatment of complicated skin and soft tissue infections including diabetic foot infections.